129 related articles for article (PubMed ID: 9598508)
1. Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups.
Stamey TA; Sözen TS; Yemoto CM; McNeal JE
J Urol; 1998 Jun; 159(6):2009-12. PubMed ID: 9598508
[TBL] [Abstract][Full Text] [Related]
2. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
3. [The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification].
Koh H; Maru N; Muramoto M; Wheeler TM; Scardino PT; Ohori M
Nihon Hinyokika Gakkai Zasshi; 2002 Jul; 93(5):595-601. PubMed ID: 12174634
[TBL] [Abstract][Full Text] [Related]
4. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
[TBL] [Abstract][Full Text] [Related]
5. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics.
Noguchi M; Stamey TA; Neal JE; Yemoto CE
J Urol; 2000 Jun; 163(6):1751-5. PubMed ID: 10799175
[TBL] [Abstract][Full Text] [Related]
6. Are prostate carcinoma clinical stages T1c and T2 similar?
Billis A; Magna LA; Watanabe IC; Costa MV; Telles GH; Ferreira U
Int Braz J Urol; 2006; 32(2):165-71. PubMed ID: 16650293
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens.
Stamey TA; Yemoto CM; McNeal JE; Sigal BM; Johnstone IM
J Urol; 2000 Apr; 163(4):1155-60. PubMed ID: 10737486
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer.
Ramos CG; Carvalhal GF; Smith DS; Mager DE; Catalona WJ
J Urol; 1999 May; 161(5):1525-9. PubMed ID: 10210388
[TBL] [Abstract][Full Text] [Related]
9. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C).
Epstein JI; Walsh PC; Brendler CB
J Urol; 1994 Nov; 152(5 Pt 2):1721-9. PubMed ID: 7523719
[TBL] [Abstract][Full Text] [Related]
10. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes.
Stamey TA; Donaldson AN; Yemoto CE; McNeal JE; Sözen S; Gill H
J Urol; 1998 Dec; 160(6 Pt 2):2412-7. PubMed ID: 9817394
[TBL] [Abstract][Full Text] [Related]
11. Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens--a different view.
Elgamal AA; Van Poppel HP; Van de Voorde WM; Van Dorpe JA; Oyen RH; Baert LV
J Urol; 1997 Jan; 157(1):244-50. PubMed ID: 8976263
[TBL] [Abstract][Full Text] [Related]
12. Comparison of T1c versus T2 prostate cancers in Japanese patients undergoing radical prostatectomy.
Furuya Y; Ohta S; Sato N; Kotake T; Masai M
Int Urol Nephrol; 2002; 33(1):73-6. PubMed ID: 12090344
[TBL] [Abstract][Full Text] [Related]
13. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
14. Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis.
Lerner SE; Seay TM; Blute ML; Bergstralh EJ; Barrett D; Zincke H
J Urol; 1996 Mar; 155(3):821-6. PubMed ID: 8583584
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate.
Carter HB; Sauvageot J; Walsh PC; Epstein JI
J Urol; 1997 Jun; 157(6):2206-9. PubMed ID: 9146616
[TBL] [Abstract][Full Text] [Related]
16. Should pathologists continue to use the current pT2 substaging system for reporting of radical prostatectomy specimens?
Billis A; Meirelles LL; Freitas LL; Magna LA; Reis LO; Ferreira U
Int Urol Nephrol; 2011 Sep; 43(3):707-14. PubMed ID: 21336958
[TBL] [Abstract][Full Text] [Related]
17. Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4 to 10 ng./ml.
Geary ES; Stamey TA
J Urol; 1996 Sep; 156(3):1056-8. PubMed ID: 8709306
[TBL] [Abstract][Full Text] [Related]
18. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations.
Ohori M; Wheeler TM; Scardino PT
Cancer; 1994 Jul; 74(1):104-14. PubMed ID: 7516262
[TBL] [Abstract][Full Text] [Related]
19. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation.
Stokes SH
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):129-36. PubMed ID: 10758314
[TBL] [Abstract][Full Text] [Related]
20. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
